Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Antiviral therapy stories

Oct 27, 2026

Study finds long-acting cabotegravir and rilpivirine maintains HIV viral suppression

Research presented at IDWeek shows that long-acting injectable antiretroviral therapy combining cabotegravir and rilpivirine consistently maintains virologic suppression in adults with HIV who were previously virologically suppressed. The real-world study addresses questions about the effectiveness of switching from oral to injectable ART.

Oct 27, 2026·2 sources
00
Oct 22, 2026

FDA approves dolutegravir HIV drug for newborns based on international clinical trial

The U.S. Food and Drug Administration has approved dolutegravir, a second-generation antiretroviral drug, for use in newborns exposed to HIV-1. The approval was informed by an international phase 1 study conducted through the IMPAACT Network that established safe and effective dosing regimens for full-term neonates.

Oct 22, 2026·3 sources
00
Oct 20, 2026

FDA approves GSK's hepatitis B drug Hibsago

The FDA approved GSK's hepatitis B drug Hibsago, allowing patients with the liver infection to maintain viral control after stopping long-term treatment. The approval offers a new treatment option for chronic hepatitis B patients.

Oct 20, 2026·2 sources
00
Aug 11, 2026

England reaches 100,000 hepatitis C treatments as elimination target moves within reach

New data from NHS England shows the country is nearing elimination of hepatitis C as a public health threat, with 80% of known cases cured. The progress is attributed to widespread testing initiatives including A&E blood tests, GP registration screening, and free at-home tests, along with a pioneering NHS drug deal with pharmaceutical companies.

Aug 11, 2026·6 sources
00
Jul 28, 2026

Remdesivir treatment reduces cardiovascular complications in kidney transplant recipients with COVID-19

Study finds that kidney transplant recipients treated with remdesivir within a week of COVID-19 diagnosis and receiving at least three consecutive days of therapy experienced fewer cardiovascular complications compared to those who did not receive the antiviral treatment.

Jul 28, 2026·1 source
00

Top claims

  • ▪An OPERA cohort study of 7,995 HIV-positive adults presented by Dr. Ricky Hsu at IDWeek in October 2026 demonstrated that long-acting cabotegravir and rilpivirine maintained virologic suppression.
  • ▪Discontinuations of long-acting cabotegravir and rilpivirine in the OPERA study were infrequently caused by injection-site reactions or lack of efficacy, resulting more often from logistical and insurance challenges.
  • ▪The FDA approved long-acting cabotegravir and rilpivirine in 2021 as a complete injectable antiretroviral therapy alternative to daily oral HIV treatment.

Subtopics

Drug Policy, Pricing & Approval4Infectious disease3Chronic disease management2Drug Approval and Clinical Trials2FDA drug approval2Infectious Disease and Outbreaks2Cardiovascular health.1Child health1Clinical trials1Drug development1FDA regulatory approval1Global health1Health screening1Healthcare Access and Insurance1Hepatitis B treatment1Injectable drug delivery devices1Medication adherence1Observational research1Organ transplantation1Outbreak monitoring & surveillance1Pharmaceutical Industry1Pharmaceutical pricing1Preventive medicine1Public health1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories